ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Screening for Hematology Branch Protocols

This study is currently recruiting patients.

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: Warren G Magnuson Clinical Center (CC)

Purpose

This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.

After subjects complete the screening process, they will be offered the opportunity to participate in an active research study, or if no appropriate studies are available information and recommendations will be provided for other treatment options.

Condition
Anemia
Hematologic Neoplasm
Neutropenia
Pancytopenia
Thrombocytopenia

MedlinePlus related topics:  Anemia;   Bleeding Disorders;   Blood and Blood Disorders;   Cancer;   Cancer Alternative Therapy

Study Type: Observational
Study Design: Screening

Official Title: Screening Protocol for Subjects Being Evaluated for Hematology Branch Protocols

Further Study Details: 

Expected Total Enrollment:  999999

Study start: December 6, 1996

This protocol is designed for screening of subjects before a decision can be made as to their eligibility for one of the active Hematology Branch research protocols. Its purpose is to allow detailed investigation into the hematologic or oncologic problems of these subjects, and the status of other organ systems that would determine their ability to safely tolerate specific aspects of active research protocols. It allows investigation as to whether a donor is HLA matched, fit to receive G-CSF, and fit to undergo apheresis and therefore eligible to participate as a donor on a bone marrow transplant protocol. It also allows the investigation as to whether subjects are eligible for participation as normal volunteer based on protocol eligibility criteria that requires generally good health status by history or physical exam findings, or laboratory assessments. After completion of this screening process, the subject will either be offered a chance to participate in an active research protocol, or if no appropriate protocol is identified, subjects with hematologic or oncologic disease will have recommendations for other treatment options relayed to the primary or referring physician.

Eligibility

Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA:
Subjects will be entered on this protocol at the time of their first visit to the NIH Clinical Center outpatient clinic or inpatient service if:
The subject carries the diagnosis of a disorder for which the Hematology Branch has an active research protocol, and based on information received from an outside physician, he/she appears to meet at least preliminary eligibility criteria for that protocol.
OR
The subject is a donor for a subject for which the Hematology Branch has an active stem cell transplant protocol and based on information received from an outside physician, he/she appears to meet preliminary eligibility as a donor.
OR
The subject is a normal volunteer for which the Hematology Branch has an active study recruiting healthy normal volunteers and he/she appears to meet preliminary eligibility as a normal volunteer.
Age greater than or equal to 2.
Weight greater than 12 kg.
The subject or the subject's guardian is capable of informed consent, and willing to sign the consent form after initial counseling by clinical staff. Separate consent forms for all interventional or surgical procedures will be obtained after explanation of the specific procedure.

Location and Contact Information


Maryland
      National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States; Recruiting
Patient Recruitment and Public Liaison Office  1-800-411-1222    prpl@mail.cc.nih.gov 
TTY  1-866-411-1010 

More Information

Detailed Web Page

Study ID Numbers:  970041; 97-H-0041
Record last reviewed:  November 21, 2003
Last Updated:  November 21, 2003
Record first received:  November 3, 1999
ClinicalTrials.gov Identifier:  NCT00001620
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-18
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act